Medicenna Therapeutics (TSX:MDNA) Beta: 2.8912 (As of Jun. 25, 2026)


TSX:MDNA Medicenna Therapeutics Corp TSX:MDNA
26 GF Score
Price C$0.41
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Beta?

Medicenna Therapeutics TSX:MDNA +1.23% 26 Beta is 2.8912 as of Jun. 25, 2026. GuruFocus rates TSX:MDNA with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Medicenna Therapeutics's Beta is 2.8912.


Medicenna Therapeutics  (TSX:MDNA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Medicenna Therapeutics Beta Related Terms


Medicenna Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Beta Chart

Medicenna Therapeutics Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 -0.25 0.82 2.84 2.77

Medicenna Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.75 2.77 3.10 2.66 3.37

TSX:MDNA vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Medicenna Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Beta falls into.


TSX:MDNA
26GF Score
Medicenna Therapeutics Corp TSX:MDNA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.8912 mean?
Medicenna Therapeutics (TSX:MDNA) has a Beta of 2.8912 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Beta too high?
Medicenna Therapeutics' current Beta is 2.8912. Overall, Medicenna Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Beta compare to VRTX and REGN?
Medicenna Therapeutics' Beta of 2.8912 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Beta is 2.8912. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (TSX:MDNA) has a current Beta of 2.8912. The current Beta is 2.8912. Medicenna Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Medicenna Therapeutics (TSX:MDNA), the current Beta is 2.8912 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNAF:USA
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
26GF Score

Get the complete analysis for TSX:MDNA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.41
Price